Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms... Show more
ICLR broke above its upper Bollinger Band on January 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 37 similar instances where the stock broke above the upper band. In of the 37 cases the stock fell afterwards. This puts the odds of success at .
The 10-day RSI Indicator for ICLR moved out of overbought territory on January 08, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 64 cases where ICLR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ICLR turned negative on January 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICLR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved above the 0 level on January 13, 2026. You may want to consider a long position or call options on ICLR as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
ICLR moved above its 50-day moving average on December 22, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ICLR advanced for three days, in of 310 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 264 cases where ICLR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ICLR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.499) is normal, around the industry mean (13.332). P/E Ratio (24.702) is within average values for comparable stocks, (127.018). Projected Growth (PEG Ratio) (1.430) is also within normal values, averaging (1.939). ICLR has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (1.814) is also within normal values, averaging (12.980).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICLR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
a provider of clinical research and development services
Industry MedicalSpecialties
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AZNH | 55.89 | 0.69 | +1.26% |
| ASTRAZENECA PLC ADRHEDGED AZNH | |||
| PAPI | 26.59 | 0.06 | +0.23% |
| Parametric Equity Premium Income ETF | |||
| SOFL | 22.73 | N/A | N/A |
| 2x Daily Software Platform ETF | |||
| IGTR | 28.65 | -0.10 | -0.33% |
| Innovator Gradient Tactical Rot Str ETF | |||
| SPGM | 78.68 | -0.29 | -0.37% |
| SPDR® Portfolio MSCI Global Stk Mkt ETF | |||
A.I.dvisor indicates that over the last year, ICLR has been closely correlated with TMO. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if ICLR jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To ICLR | 1D Price Change % | ||
|---|---|---|---|---|
| ICLR | 100% | +1.74% | ||
| TMO - ICLR | 67% Closely correlated | -1.36% | ||
| RGEN - ICLR | 62% Loosely correlated | -0.65% | ||
| DHR - ICLR | 62% Loosely correlated | -1.44% | ||
| IQV - ICLR | 61% Loosely correlated | +0.29% | ||
| A - ICLR | 59% Loosely correlated | -1.13% | ||
More | ||||